Polymorphic Variants in the Vitamin D Receptor and Clinical Parameters of Rheumatoid Arthritis Patients Undergoing Anti-TNF Treatment

Wielińska, Joanna; Górna, Katarzyna; Świerkot, Jerzy; Bugaj, Bartosz; Kolossa, Katarzyna; Jeka, Sławomir; Bogunia-Kubik, Katarzyna

Polymorphic Variants in the Vitamin D Receptor and Clinical Parameters of Rheumatoid Arthritis Patients Undergoing Anti-TNF Treatment

Archivum Immunologiae et Therapiae Experimentalis

Volume 72 (2024): Issue 1 (January 2024)

By:

Joanna Wielińska, Katarzyna Górna, Jerzy Świerkot, Bartosz Bugaj, Katarzyna Kolossa, Sławomir Jeka and Katarzyna Bogunia-Kubik

Open Access

|Nov 2024

Figures & Tables

Differences in CRP and VAS parameters in relation to VDR rs1544410 genotypes (Mann–Whitney test). Data are presented as median with IQR. CRP, C-reactive protein; IQRs, interquartile ranges; VAS, visual analog scale; VDR, vitamin D receptor.

Differences in CRP and VAS parameters in relation to VDR rs731236 genotypes (Mann–Whitney test). Data are presented as median with IQR. CRP, C-reactive protein; IQRs, interquartile ranges; VAS, visual analog scale; VDR, vitamin D receptor.

Differences in the levels of 25(OH)D3 level (ng/mL) according to the presence of VDR genotypes: rs2228570 (ordinary one-way ANOVA, p = 0.014) and rs797532 (Kruskal–Wallis test, p = 0.008). 25(OH)D3, 25-hydroxyvitamin D3; VDR, vitamin D receptor.

Characteristics of patients’ subgroup

	Calcium (mg/dL)	Alkaline phosphatase (U/L)	Vitamin D3 (ng/mL)	TSH (ulU/mL)
N	56	64	54	64
Minimum	8.9	36	4.64	0.271
Median	9.7	74.5	23.67	1.201
Maximum	10.7	350	66	4.331
IQR	0.5	33.25	23.14	0.744

Characteristics of the RA patients included in the study

Number of patients	121
Age mean in years (±SD)	52.2 (13.3)
Disease duration mean in years (±SD)	13.6 (9.31)
Disease onset mean in years (±SD)	38.6 (14.0)
Sex F/M (%)	96/25 (79.3)
BMI mean (±SD)	25.7 (4.69)
RF-positive patients (%)	86.7
Anti-CCP positive patients (%)	82.4
Anti-TNF drugs:	N (%)
Adalimumab	41 (33.9)
Etanercept	48 (39.7)
Certolizumab pegol	19 (15.7)
Golimumab	9 (7.44)
Infliximab	4 (3.31)
Concomitant treatment at the start of biologic treatment	(%)
NSAIDs	73.2
MTX	83.6
Corticosteroids	82.1
Disease activity:
DAS28 before treatment, mean (±SD)	6.14 (0.713)
DAS28 after 6 months of treatment, mean (±SD)	2.63 (0.939)

Relationships between VDR rs7975232 genetic variants and vitamin D levels in RA patients

	VDR rs7975232	25(OH)D3 conc. (ng/mL)
Median (IQR)	AA	29.6 (25.34)
	AC + CC	21.54 (21.2)
	AA + AC	21.54 (17.02)
	CC	36.68 (19.87)
	AA + CC	33.33 (20.81)
	AC	19.32 (12.56)
Mann–Whitney test p-values	AA vs. AC + CC	0.1703
	AA + AC vs. CC	0.029
	AA + CC vs. AC	0.003
	AA vs. AC	0.021
	AC vs. CC	0.009
	AA vs. CC	0.324

VDR genotype and minor allele frequencies of RA patients and control group

	Genotypes						MAF			χ²		χ² p-value

SNP	RA	Controls	RA	Controls	RA	Controls	RA	Controls	1000 genomes project–CEU	RA	Controls	RA	Controls

rs1544410	AA		AG		GG		0.368	0.434	0.470	0.408	2.146	0.523	0.143
rs1544410	18	27	53	52	50	43
rs2228570	CC		CT		TT		0.438	0.422	0.429	0.006	0.417	0.937	0.518
rs2228570	38	39	60	63	23	20
rs731236	CC		CT		TT		0.360	0.409	0.400	0.869	2.920	0.351	0.087
rs731236	18	15	51	65	52	36
rs7975232	AA		AC		CC		0.483	0.496	0.404	0.068	1.692	0.794	0.193
rs7975232	33	26	59	65	29	25

Relationships between VDR rs2228570 genetic variants and vitamin D levels in RA patients

	VDR rs2228570	25(OH)D3 conc. (ng/mL)
Mean (±SD)	CC	20.69 ± 11.12
	CT	32.22 ± 16.06
	TT	22.33 ± 9.077
Median (IQR)	CC	18.47 (16.98)
	CT + TT	25.08 (22.07)
	CC + CT	23.88 (24.48)
	TT	21.54 (14.92)
p-values	CC vs. CT + TT	0.028^†
	CC + CT vs. TT	0.508^†
	CC + TT vs. CT	0.004^‡
	CC vs. CT	0.009^‡
	CT vs. TT	0.093^‡
	CC vs. TT	0.701^‡

DOI: https://doi.org/10.2478/aite-2024-0023 | Journal eISSN: 1661-4917

Journal RSS Feed

Language: English

Submitted on: Jun 28, 2024

Accepted on: Oct 18, 2024

Published on: Nov 10, 2024

Published by: Hirszfeld Institute of Immunology and Experimental Therapy

In partnership with: Paradigm Publishing Services

Publication frequency: 1 times per year

Keywords:

Rheumatoid arthritis,

Vitamin D receptor,

Single-nucleotide polymorphism,

Anti-TNF therapy,

Vitamin D level

Related subjects:

Medicine,

Basic medical science,

Biochemistry,

Immunology,

Clinical medicine,

Clinical medicine, other,

Clinical chemistry

© 2024 Joanna Wielińska, Katarzyna Górna, Jerzy Świerkot, Bartosz Bugaj, Katarzyna Kolossa, Sławomir Jeka, Katarzyna Bogunia-Kubik, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous article Volume 72 (2024): Issue 1 (January 2024)Next article

Polymorphic Variants in the Vitamin D Receptor and Clinical Parameters of Rheumatoid Arthritis Patients Undergoing Anti-TNF Treatment

Figures & Tables

Fig 1.

Fig 2.

Fig 3.

Characteristics of patients’ subgroup

Characteristics of the RA patients included in the study

Relationships between VDR rs7975232 genetic variants and vitamin D levels in RA patients

VDR genotype and minor allele frequencies of RA patients and control group

Relationships between VDR rs2228570 genetic variants and vitamin D levels in RA patients

Paradigm

My account